Nxstage Medical (NXTM) Tops Q2 EPS by 2c

Nxstage Medical (NASDAQ: NXTM) reported Q2 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $80.3 million versus the consensus estimate of $79.89 million.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c